ARTICLE | Clinical News
Abraxane paclitaxel regulatory update
July 21, 2008 7:00 AM UTC
Abraxis received Chinese marketing approval for Abraxane paclitaxel to treat metastatic breast cancer or disease relapse within 6 months after failure of adjuvant chemotherapy. Abraxis hopes to launch...